Among the aberrantly activated networks, they identified TNF/NF-κB inflammatory signaling as a key pathway activated in both malignant and nonmalignant cells and as a common pathway in MF progression, thus providing insights into the molecular basis of MPN-associated inflammation and a therapeutic approach to target aberrant inflammatory signaling in MPN. The gene discussed is NFKB1; the disease is myeloproliferative neoplasm.